Search peptides, terms, sources/
Regulatory source · 2021

Freedom of Information response FOI 21/1237, Yellow Card reports for Melanotan II products (2011-2021) and regulatory classification

About this source

Kind
Regulatory or official document
Population
Not applicable (UK-wide Yellow Card adverse-reaction reporting data)
Sample size
13 ADR reports, 2011-2021
Primary or secondary
primary
Peer review
unknown
Retraction status
None known
Date checked
14 August 2026

Limitations

The MHRA's own letter states Yellow Card inclusion does not establish causation and the scheme has an unknown, variable degree of under-reporting; the 13-report figure should not be read as true incidence.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.